Finch secures $53m to advance microbiome therapies for CDI, Autism
Finch Therapeutics, a US microbiome therapeutics company, has raised $53 million through a Series C financing round to advance its pipeline of microbial therapies, as per the latest pharma industry news. In addition to existing investors Avenir Growth Capital, Morgan Noble, Shumway Capital, and Willett Advisors, the funding for the US microbiome therapeutics More...
Pfizer to build $500m gene therapy manufacturing facility in Sanford
US pharma giant Pfizer has committed $500 million to expand its gene therapy by constructing a new gene therapy manufacturing facility in Sanford in North Carolina. Pfizer’s Sanford gene therapy facility will More...
US pharma manufacturer Conagen acquires glycoproteins production platform
US pharma manufacturer Conagen has purchased a glycoproteins production platform – a fermentation-based technology for the production of glycoproteins used for making therapeutics, for an undisclosed price. The More...
Bayer to divest animal health business to Elanco for $7.6bn
US-based veterinary pharmaceuticals producer Elanco Animal Health has agreed to acquire German drug giant Bayer’s animal health business for $7.6 billion, financed by a combination of 70% cash and 30% equity. The More...
Eiger bags FDA breakthrough therapy status for HDV drug candidate Lambda
US biopharma company Eiger BioPharmaceuticals said that peginterferon lambda (Lambda) has been granted breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of hepatitis More...
NKMax America launches SNK01-MX03 clinical trial in plaque psoriasis
SNK01-MX03 clinical trial : NKMax America, a US biotech company, has initiated a phase 1 trial called SNK01-MX03 to investigate its ex vivo expanded autologous natural killer cell therapeutic SNK in plaque psoriasis. In More...
Mexican pharma company Sanfer secures $500m investment from CDPQ
CDPQ investment in Sanfer : Mexican pharma company Sanfer has secured a $500 million minority investment from Canadian long-term institutional investor Caisse de dépôt et placement du Québec (CDPQ) to help it More...
Nabriva secures Xenleta FDA approval for community-acquired pneumonia
Xenleta FDA approval : Irish pharma company Nabriva Therapeutics has bagged approval from the US Food and Drug Administration for its semi-synthetic pleuromutilin antibiotic Xenleta (lefamulin) for the treatment More...
Celgene bags Inrebic FDA approval for myelofibrosis
Inrebic FDA approval : Celgene’s subsidiary Impact Biomedicines, has bagged approval for its oral kinase inhibitor Inrebic (fedratinib) capsules from the US Food and Drug Administration (FDA) for the treatment More...
Alfasigma USA launches IBS-C drug ZELNORM in US
Alfasigma USA has launched ZELNORM (tegaserod) tablets in the US as a prescription drug for irritable bowel syndrome with constipation (IBS-C) in adult women aged under 65 years. ZELNORM was acquired by Alfasigma More...